Utilizing registries in systemic lupus erythematosus clinical research

Expert Review of Clinical Immunology

Volumn 8, Issue 4, 2012, Pages 353-360

  Villa Blanco, Ignacio ^a   Calvo Alén, Jaime ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

clinical research; epidemiology; registry; systemic lupus erythematosus

Indexed keywords

CASE CONTROL STUDY; CLINICAL RESEARCH; COHORT ANALYSIS; DATA BASE; DISEASE REGISTRY; HUMAN; PREVALENCE; REVIEW; STUDY DESIGN; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; REGISTRIES; YOUNG ADULT;

EID: 84861363601     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.12.20     Document Type: Review

References (71)

1. Gliklich RE, Dreyer NA. Registries For Evaluating Patient Outcomes: A User's Guide (2nd Edition). AHRQ Publication No. 10-EHC049, Agency for Healthcare Research and Quality, Rockville, MD, USA (2010).
2. De Rooy DPC, van Der Linden MPM, Kneven R, Huizinga TWJ, van Der Helm-van Mil AHM
3. Mariette X, Gottenberg JE, Ravaud P, Combe B. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology 50, 222-229 (2011).
4. Wolfe F, Michaud K. The national data bank for rheumatic diseases: A multi registry rheumatic disease data bank. Rheumatology 50, 16-24 (2011).
5. Kremer JM. The CORRONA database. Autoimmun. Rev. 5, 46-54 (2006).
6. McCarty DJ, Manzi S, Medsger TA Jr, Ramsey-Goldman R, LaPorte RE, Kwoh K. Incidence of systemic lupus erythematosus. Arthritis Rheum. 38, 1260-1270 (1995).
7. Lu LJ, Wallace DJ, Navarra SV, Weisman MH. Lupus registries: evolution and challenges. Semin. Arthritis Rheum. 39, 224-245 (2010).
8. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies and the hierarchy of research designs. N. Engl. J. Med. 342, 1887-1892 (2000).
9. Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? N. Engl. J. Med. 342, 1907-1909 (2000).
10. Feinstein AR. An additional basic science for clinical medicine: IV. The development of clinimetrics. Ann. Intern. Med. 99, 843-848 (1983).
11. White E, Hunt JR, Casso D. Exposure measurement in cohort studies: the challenges of prospective data collection. Epidemiol. Rev. 20, 43-56 (1998).
12. Sackett DL, Haynes RB, Tugwell P. Clinical Epidemiology. Little, Brown and Company, MA, USA, 228 (1985).
13. Hennekens CH, Buring JE. Epidemiology in Medicine (1st Edition). Little, Brown and Company, MA, USA (1987).
14. Rothman K, Greenland S. Modern Epidemiology (3rd Edition). Lippincott Williams & Wilkins, PA, USA (1998).
15. Szklo M. Population-based cohort studies. Epidemiolo. Rev. 20, 81-90 (1998).
16. Salim A, Hultman C, Sparén P, Reilly M. Combining data from 2 nested case- control studies of overlapping cohorts to improve efficiency. Biostatistics 10, 70-79 (2009).
17. Biesheuvel CJ, Vergouwe Y, Oudega R, Hoes AW, Grobbee DE, Moons KGM. Advantages of the nested case-control design in diagnostic research. BMC Med. Res. Methodol. 8, 48 (2008).
18. Kulathinal S, Karvanen J, Saarela O, Kuulasmaa K. For the MORGAM project. Case-cohort design in practice - experiences from the MORGAM project. Epidemiol. Perspect. Innovat. 4, 15 (2007).
19. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 73, 1-11 (1986).
20. Petri M. Clinical research in systemic lupus erythematosus: Immediate relevance to clinical practice. Int. J. Rheumat. Dis. 14, 1-5 (2011).
21. Bookman AAM, Urowitz MB, Koehler BE. The bimodal pattern of mortality in systemic lupus erythematosus (SLE). J. Rheumatol. 1, 57 (1974) (Abstract).
22. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodalmortality pattern of systemic lupus erythematosus. Am. J. Med. 60, 221-225 (1976).
23. Urowitz MB, Ibañez D, Gladman DD. Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J. Rheumatol. 34, 70-75 (2007).
24. Bajaj S, Albert L, Gladman DD et al. Serial renal biopsy in systemic lupus erythematosus. J. Rheumatol. 27, 2822-2826 (2000).
25. Urowitz MB, Gladman DD. Contributions of observational cohort studies in systemic lupus erythematosus: the University of Toronto lupus clinic experience. Rheumatol. Dis. Clin. N. Am. 31, 211-221 (2005).
26. Nikpour M, Urowitz MB, Ibañez D, Gladman D. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum. 61, 1152-1158 (2009).
27. Petri M. Lupus in Baltimore: evidence-based 'clinical pearls' from the Hopkins lupus cohort. Lupus 14, 970-973 (2005).
28. Barr S, Zonana-Nacach A, Magder L, Petri M. Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum. 42, 2682-2688 (1999).
29. Petri M, Perez-Gutthann S, Longenecker JC, Hochberg MC. Morbidity of systemic lupus erythematosus: Role of race and socioeconomic status. Am. J. Med. 91, 345-353 (1991).
30. Petri M, Howard D, Repke J, Goldman DW. The Hopkins lupus pregnancy center: 1987-1991 update. Am. J. Reprod. Immunol. 28, 188-191 (1992).
31. Petri M, Lakatta C, Magder L, Goldman DW. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis. Am. J. Med. 96, 254-259 (1994).
32. Petri M, Rheinschmidt M, Whiting- O'Keefe Q, Hellmann D, Corash L. The frequency of lupus anticoagulant in systemic lupus erythematosus: A study of 60 consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody. Ann. Intern. Med. 106, 524-531 (1987).
33. Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins lupus cohort. Thromb. Res. 114, 593-595 (2004).
34. Siedner MJ, Gelber AC, Rovin BH et al. Diagnostic accuracy study of urine dipstick in relation to 24-hour measurement as a screening tool for proteinuria in lupus nephritis. J. Rheumatol. 35, 84-90 (2008).
35. Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus. Med. (Baltimore) 85, 147-156 (2006).
36. Uribe AG, McGwin G Jr, Reveille JD, Alarcón GS What have we learned from a 10-year experience with the LUMINA (Lupus in Minorities; Nature vs. Nurture) cohort? Where are we heading? Autoimmun. Rev. 3, 321-329 (2004).
37. Fessler BJ, Alarcón GS, McGwin G Jr et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 52, 1473-1480 (2005).
38. Fernández M, Calvo-Alén J, Bertoli AM et al. Systemic lupus erythematosus in a multiethnic U.S. cohort (LUMINA LII): Relationship between vascular events and the use of hormone replacement therapy in postmenopausal women. J. Clin. Rheumatol. 13, 261-265 (2007).
39. Fernández M, Alarcón GS, Calvo-Alén J et al. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum. 57, 576-584 (2007).
40. Alarcón GS, McGwin G, Bertoli AM et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic U.S. cohort (LUMINA L). Ann. Rheumatol. Dis. 66, 1168-1172 (2007).
41. Bertoli AM, Alarcon GS, Calvo-Alén J, Fernandez M, Vila LM, Reveille JD. Systemic lupus erythematosus in a multiethnic US cohort. XXXIII. Clinical [corrected] features, course, and outcome in patients with late-onset disease. Arthritis Rheum. 54, 1580-1587 (2006).
42. Tucker L, Uribe A, Fernández M et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: Results of a nested matched case-control study within LUMINA, a multiethnic U.S. cohort (LUMINA LVII). Lupus 17, 314-322 (2008).
43. Andrade RM, Alarcón GS, Fernández M et al. Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic U.S. cohort. Arthritis Rheum. 56, 622-630 (2007).
44. Pons-Estel GJ, Gonzalez LA, Zhang J et al. Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort. Rheumatology 48, 817-822 (2009).
45. Calvo-Alén J, McGwin G, Toloza S et al. Systemic lupus erythematosus in a multiethnic U.S. cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: Results of a nested matched case-control study. Ann. Rheumatol. Dis. 65, 785-790 (2006).
46. Pons-Estel BA, Catoggio LJ, Cardiel MH et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among " Hispanics". Medicine (Baltimore) 83, 1-17 (2004).
47. Shinjo SK, Bonfá E, Wojdyla D et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum. 62, 855-862 (2010).
48. Alarcón GS, McGwin G Jr, Petri M et al. Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus 11, 95-101 (2002).
49. Alarcón GS, McGwinJr G, Petri M et al. Time to renal disease and end-stage renal disease in PROFILE: A multiethnic lupus cohort. PLoS Med. 10, 1949-1956 (2006).
50. Peschken CA, Katz SJ, Silverman E et al. The 1000 Canadian faces of lupus: determinants of disease outcome in a large multiethnic cohort. J. Rheumatol. 36, 1200-1208 (2009).
51. Lalani S, Pope J, De León F, Peschken C. Clinical features and prognosis of late-onset systemic lupus erythematosus: Results from the 1000 faces of lupus study. J. Rheumatol. 37, 38-44 (2010).
52. Cervera R, Khamashta MA, Font J et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Med. (Baltimore) 82, 299-308 (2003).
53. Cervera R, Abarca-Costalago M, Abramovicz D et al. (European working party on systemic lupus erythematosus). Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project". Autoimmun. Rev. 5, 180-186 (2006).
54. Houssiau FA, Vasconcelos C, D'Cruz D et al. The 10-year follow-up data of the Euro-Lupus nephritis trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann. Rheumatol. Dis. 69, 61-64 (2010).
55. Gladman D, Ginzler E, Goldsmith C et al. Systemic lupus international collaborative clinics: development of a damage index in systemic lupus erythematosus. J. Rheumatol. 19, 1820-1821 (1992).
56. Gladman D, Ginzler E, Goldsmith C et al. The development and initial validation of the SLICC/ACR damage index for SLE. Arthritis Rheum. 39, 363-369 (1996).
57. Urowitz M, Gladman D, Ibañez D et al. Atherosclerotic vascular events in a multinational inception cohort of SLE. Arthritis Care Res. (Hoboken) 62, 881-887 (2010).
58. Urowitz MB, Gladman DD, Ibañez D et al. Evolution of disease burden over five years in a multicentre inception SLE cohort. Arthritis Care Res. 64(1), 132-137 (2012).
59. Hanly JG, Urowitz MB, Sanchez-Guerrero J et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: An international inception cohort study. Arthritis Rheum. 56, 265-273 (2007).
60. Hanly JG, Urowitz MB, Siannis F et al. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: Results from an internationalinception cohort study. Arthritis Rheum. 58, 843-853 (2008).
61. Hanly JG, Urowitz MB, Su L et al. Prospective analysis of neuropsychiatric events in an international disease inception cohort of SLE patients. Ann. Rheumatol. Dis. 69, 529-535 (2010).
62. Hanly JG, Urowitz MB, Jackson D et al. SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in SLE. Ann. Rheumatol. Dis. 70, 961-967 (2011).
63. Yelin E, Trupin L, Katz P et al. Work dynamics among persons with SLE. Arthritis Care Res. 57, 56-63 (2007).
64. Yazdany J, Tonner C, Trupin L et al. Provision of preventive health care in systemic lupus erythematosus: data from a large observational cohort study. Arthritis Res. Thera. 12(3), R84 (2010).
65. Thibauly Flesher DL, Sun X, Behrens TW, Graham RR, Criswell LA. Recent advances in the genetics of SLE. Exp. Clin. Immunol. 6, 461-479 (2010).
66. Taylor KE, Chung SA, Graham RR et al. Risk alleles for SLE in a large case-control collection and associations with clinical subphenotypes. PLoS Genet. 7(2), E1001311 (2011).
67. Adrianto I, Wen F, Templeton A et al. Association between a functional variant downstream of TNFAIP3 and systemic lupus erythematosus. Nat. Genet. 43, 253-258 (2011).
68. Tan W, Sunahori K, Zhao J et al. Association of PPP2CA polymorphisms with SLE susceptibility in multiple ethnic groups. Arthritis Rheum. 63, 2755-2763 (2011).
69. Rasmussen A, Sevier S, Kelly JA et al. The lupus family registry and repository. Rheumatology 50, 47-59 (2011).
70. Bloom S Registries in chronic disease: coming your way soon? Rheumatology 50, 4-5 (2011).
71. Agmon-Levin N, Mosca M, Petri M, Shoenfeld Y. Systemic lupus erythematosus one disease or many? Autoimmune Rev. doi:10.1016/j.autrev.2011.10. 020 (2011) (Epub ahead of print).